2025 / 05

Next Paper
DOI: 10.24075/brsmu.2025.054
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Susceptibility of the nontuberculous mycobacteria circulating in Russia to bedaquiline

Smirnova TG1, Andreevskaya SN1, Larionova EE1, Zaytseva AS1, Kiseleva EA1, Ustinova VV1, Chernousova LN1, Ergeshov AE1,2
About authors

1 Central Tuberculosis Research Institute, Moscow, Russia

2 Russian University of Medicine, Moscow, Russia

Correspondence should be addressed: Tatiana G. Smirnova
Yauzskaya alleya, 2, str. 1А, Moscow, 107564, Russia; ur.liam@aktat_s

About paper

Funding: the study was conducted under the State Assignment of the Central Tuberculosis Research Institute, R&D project: 123061500080-6 “Developing an Import-Independent Technology to Determine Minimal Inhibitory Concentrations of Antibacterial Drugs Effective Against the Clinically Significant Nontuberculous Mycobacterial Species”

Author contribution: Chernousova LN, Ergeshov AЕ — study design; Ustinova VV, Kiseleva EA — experimental procedure; Smirnova TG — data analysis, manuscript writing; Larionova EE — data analysis; Zaytseva AS — literature review, manuscript draft writing; Andreevskaya SN — data analysis; all authors contributed to the discussion.

Compliance with ethical standards: the study was conducted in accordance with the principles of the Declaration of Helsinki (1964) and its further revisions.

Received: 2025-10-02 Accepted: 2025-10-18 Published online: 2025-10-30
|
  1. Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev. 2014; 27: 727–52.
  2. Raju RM, Raju SM, Zhao Y, Rubin EJ. Leveraging advances in tuberculosis diagnosis and treatment to address nontuberculous mycobacterial disease. Emerg Infect Dis. 2016; 22 (3): 365–9.
  3. Otten TF, Vasilev AV. Mikobakterioz. SPb: Medicinskaya pressa, 2005; 224 s. Russian.
  4. Litvinov VI, Makarova MV, Krasnova MA. Netuberkuleznye mikobakterii. M.: MNPCBT, 2008; 256 s. Russian.
  5. Litvinov VI, Bogorodskaya EM, Borisov SE. Netuberkuleznye mikobakterii, mikobakteriozy M.: MNPCBT, 2014; 256 s. Russian.
  6. Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis. 2014; 18: 1370–7.
  7. Wu ML, Aziz DB, Dartois V, Dick T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018; 23: 1502–19.
  8. Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis. 2019; 13: e0007083.
  9. Yilmaz N, Yilmazel Ucar E, Saglam L. Mycobacterium tuberculosis and nontuberculous mycobacteria coinfection of the lungs. Turk Thorac J. 2017; 18: 23–6.
  10. Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J App Basic Med Res. 2013; 3: 1–2.
  11. Aguilar-Ayala DA, Cnockaert M, André E, Andries K, Gonzalez-Y-Merchand JA, Vandamme P et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol. 2017; 66: 1140–3.
  12. Martin A, Godino IT, Aguilar-Ayala DA, Mathys V, Lounis N, Villalobos HR. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria. J Med Microbiol. 2019; 68 (8): 1137–9.
  13. Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother. 2017; 61 (5): e02627–16.
  14. Yu X, Gao X, Li C, Luo J, Wen S, Zhang T. et al. In vitro activities of bedaquiline and delamanid against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob Agents Chemother. 2019; 63 (8): e00031–19.
  15. Makarova MV, Mihajlova YuD, Hachaturyanc EN, Litvinov VI. Izuchenie lekarstvennoj chuvstvitel'nosti k bedakvilinu bystrorastushchih mikobakterij kompleksa M. chelonae–M.abscessus. Tuberkulez i social'no znachimye zabolevaniya. 2022; 10 (4): 42–49. Russian.
  16. Makarova MV, Mihajlova YuD, Hachatur'yanc EN, Litvinov VI. Lekarstvennaya chuvstvitel'nost' k bedakvilinu shtammov M.kansasii, vydelennyh v protivotuberkuleznyh uchrezhdeniyah Moskvy. Epidemiologiya i vakcinoprofilaktika. 2023; 22 (3): 64–69. Russian.
  17. Makarova MV, Mihajlova YuD, Sviridenko MA, Hachatur'yanc EN, Litvinov VI. Izuchenie aktivnosti bedakvilina in vitro v otnoshenii Mycobacterium fortuitum complex. Tuberkulez i social'no znachimye zabolevaniya. 2024; 12 (1): 30–35. Russian.
  18. Smirnova T, Ustinova V, Andreevskaya S, Larionova E, Kiseleva E, Chernousova L, et al. Evaluation of a new assay for nontuberculous mycobacteria species identification in diagnostic material and cultures. Tuberculosis (Edinb). 2021; 130: 102124.
  19. Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex. Geneva: World Health Organization, 2022.
  20. Kralik P, Beran V, Pavlik I. Enumeration of Mycobacterium avium subsp. paratuberculosis by quantitative real-time PCR, culture on solid media and optical densitometry. BMC Res Notes. 2012; 5: 114.
  21. Jaffré J, Aubry A, Maitre T, Morel F, Brossier F, Robert J et al. Rational choice of antibiotics and media for Mycobacterium avium complex drug susceptibility testing. Front Microbiol. 2020; 11: 81.
  22. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 3rd ed. CLSI standard document M24. Wayne (PA): Clinical and Laboratory Standards Institute; 2018.
  23. Wang M, Men P, Zhang W, Wu J, Gu Y, Wang F, et al. Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study. J Glob An-timicrob Resist. 2024; 37: 135–40.